<DOC>
	<DOCNO>NCT00631995</DOCNO>
	<brief_summary>This study aim study quadrivalent meningococcal ( A , C , Y , W-135 ) Tetanus Protein Conjugate Vaccine ( TetraMen-T ) formulations Toddlers . Primary Objectives : Safety Immunogenicity : To describe safety immunogenicity profile : - A single dose formulation TetraMen-T vaccine - A single dose NeisVac-C® vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine Toddlers</brief_title>
	<detailed_description>The study design evaluate safety profile immunogenicity response single dose TetraMen-T toddler .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Subject healthy , determined medical history physical assessment . Aged 12 month ( ± 21 day ) day inclusion . Institutional Review Board ( IRB ) approve informed consent form sign subject 's parent/legal guardian . Able attend schedule visit comply trial procedure . Exclusion Criteria : Serious acute chronic disease ( e.g. , cardiac , renal , metabolic , rheumatologic , psychiatric , hematologic , autoimmune disorder , diabetes , atopic condition , congenital defect , convulsion , encephalopathy , blood dyscrasia , leukemia , lymphomas type , malignant neoplasm affect bone marrow lymphatic system , acute untreated tuberculosis ) could interfere trial conduct completion . Known suspected impairment immunologic function . Acute medical illness within last 72 hour , temperature ≥ 37.5ºC ( axillary ) time enrollment ( temporary contraindication ) . History document invasive meningococcal disease previous meningococcal vaccination . Known human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C seropositivity report parent legal guardian . Received either immune globulin blood product within last 3 month , receive injected oral corticosteroid immunomodulator therapy within 6 week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day individual ( e.g. , asthmatic ) short schedule oral steroid last 3 4 day may include trial long receive one course within last two week prior enrollment . Topical steroid include exclusion criterion . Anticipated receive oral inject antibiotic therapy within 72 hour prior study blood draw . Topical antibiotic antibiotic drop include exclusion criterion . Suspected known hypersensitivity vaccine component . Thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination . Parent legal guardian unable unwilling comply stu dy procedure . Participation another interventional clinical trial 30 day precede enrollment , participation another clinical trial involve investigation drug , vaccine , medical procedure , medical device subject 's trial period . Diagnosed condition , opinion investigator , would pose health risk subject interfere evaluation vaccine . Received vaccine 30day period prior receipt study vaccine , schedule receive vaccination influenza vaccination hyposensitization therapy 30day period receipt study vaccine . Hyposensitization therapy influenza vaccination may receive 14 day 14 day receive study vaccine . History seizure , include febrile seizure , neurologic disorder . Personal family history GuillainBarré Syndrome ( GBS ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Neisseria meningitidis</keyword>
</DOC>